DZ3266A1 - Pyrido[2,3-d]pyrimidine-2,7-diamine inhibiteurs de kinase - Google Patents

Pyrido[2,3-d]pyrimidine-2,7-diamine inhibiteurs de kinase

Info

Publication number
DZ3266A1
DZ3266A1 DZ013266A DZ013266A DZ3266A1 DZ 3266 A1 DZ3266 A1 DZ 3266A1 DZ 013266 A DZ013266 A DZ 013266A DZ 013266 A DZ013266 A DZ 013266A DZ 3266 A1 DZ3266 A1 DZ 3266A1
Authority
DZ
Algeria
Prior art keywords
pyrido
pyrimidine
diamine
kinase inhibitors
kinase
Prior art date
Application number
DZ013266A
Other languages
English (en)
Inventor
Richard J Booth
Ellen M Dobrusin
Vara Prasad V Josyula
Dennis J Mcnamara
Peter L Toogood
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3266A1 publication Critical patent/DZ3266A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
DZ013266A 2000-01-25 2001-01-23 Pyrido[2,3-d]pyrimidine-2,7-diamine inhibiteurs de kinase DZ3266A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
PCT/IB2001/000069 WO2001055147A1 (fr) 2000-01-25 2001-01-23 Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase

Publications (1)

Publication Number Publication Date
DZ3266A1 true DZ3266A1 (fr) 2001-08-02

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013266A DZ3266A1 (fr) 2000-01-25 2001-01-23 Pyrido[2,3-d]pyrimidine-2,7-diamine inhibiteurs de kinase

Country Status (34)

Country Link
EP (1) EP1254137A1 (fr)
JP (1) JP4047010B2 (fr)
KR (1) KR20020065939A (fr)
CN (1) CN1395578A (fr)
AP (1) AP2002002586A0 (fr)
AR (1) AR030044A1 (fr)
AU (1) AU2542501A (fr)
BG (1) BG106850A (fr)
BR (1) BR0107751A (fr)
CA (1) CA2397961C (fr)
CO (1) CO5261549A1 (fr)
CR (1) CR6706A (fr)
CZ (1) CZ20022475A3 (fr)
DZ (1) DZ3266A1 (fr)
EA (1) EA200200643A1 (fr)
EE (1) EE200200405A (fr)
GT (1) GT200100016A (fr)
HN (1) HN2001000013A (fr)
HU (1) HUP0204141A3 (fr)
IL (1) IL150545A0 (fr)
IS (1) IS6443A (fr)
MA (1) MA26868A1 (fr)
MX (1) MXPA02007221A (fr)
NO (1) NO20023527L (fr)
OA (1) OA12161A (fr)
PA (1) PA8510701A1 (fr)
PE (1) PE20011066A1 (fr)
PL (1) PL356802A1 (fr)
SK (1) SK10632002A3 (fr)
SV (1) SV2002000294A (fr)
TN (1) TNSN01014A1 (fr)
WO (1) WO2001055147A1 (fr)
YU (1) YU50402A (fr)
ZA (1) ZA200205879B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CZ20031125A3 (cs) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Nové sloučeniny
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
PL373339A1 (en) 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
MXPA05005547A (es) * 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CN101014600A (zh) * 2004-09-21 2007-08-08 霍夫曼-拉罗奇有限公司 用作蛋白激酶抑制剂的6－(2－烷基－苯基)－吡啶并[2,3－d]嘧啶类
US7479558B2 (en) 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
EP1868612A4 (fr) 2005-03-25 2010-03-24 Glaxo Group Ltd Nouveaux composes
PE20100741A1 (es) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
CN101243081A (zh) * 2005-07-21 2008-08-13 霍夫曼-拉罗奇有限公司 作为PTP1B抑制剂的吡啶并[2,3-d]嘧啶-2,4-二胺化合物
RU2008108898A (ru) * 2005-08-09 2009-09-20 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназы
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (fr) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
EA201100879A1 (ru) * 2008-12-01 2012-01-30 Мерк Патент Гмбх Производные пиридопиримидина в качестве ингибиторов аутотаксина
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EP3733184B1 (fr) * 2013-03-14 2023-08-30 Icahn School of Medicine at Mount Sinai Composés de pyrimidine pour l'utililisation dans la traitment de cancer
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0790997B1 (fr) * 1994-11-14 2000-03-22 Warner-Lambert Company 6-ARYLE PYRIDO[2,3-d]PYRIMIDINES ET NAPHTYRIDINES DESTINEES A L'INHIBITION DE LA PROLIFERATION CELLULAIRE INDUITE PAR PROTEINE TYROSINE KINASE
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ID27589A (id) * 1998-05-26 2001-04-12 Warner Lambert Comapny Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular

Also Published As

Publication number Publication date
AU2542501A (en) 2001-08-07
JP4047010B2 (ja) 2008-02-13
MXPA02007221A (es) 2002-11-29
CA2397961A1 (fr) 2001-08-02
CZ20022475A3 (cs) 2003-03-12
CA2397961C (fr) 2008-08-26
CR6706A (es) 2005-04-04
EP1254137A1 (fr) 2002-11-06
HUP0204141A2 (hu) 2003-04-28
NO20023527L (no) 2002-09-10
CN1395578A (zh) 2003-02-05
PE20011066A1 (es) 2001-10-22
PL356802A1 (en) 2004-07-12
WO2001055147A1 (fr) 2001-08-02
TNSN01014A1 (fr) 2005-11-10
NO20023527D0 (no) 2002-07-24
SK10632002A3 (sk) 2003-06-03
JP2003523357A (ja) 2003-08-05
ZA200205879B (en) 2003-09-29
CO5261549A1 (es) 2003-03-31
IL150545A0 (en) 2003-02-12
PA8510701A1 (es) 2002-12-11
YU50402A (sh) 2005-11-28
KR20020065939A (ko) 2002-08-14
AR030044A1 (es) 2003-08-13
MA26868A1 (fr) 2004-12-20
AP2002002586A0 (en) 2002-09-30
HUP0204141A3 (en) 2005-03-29
IS6443A (is) 2002-06-25
EE200200405A (et) 2003-12-15
BG106850A (bg) 2003-02-28
GT200100016A (es) 2001-10-19
OA12161A (en) 2006-05-08
EA200200643A1 (ru) 2002-12-26
HN2001000013A (es) 2001-06-18
SV2002000294A (es) 2002-07-16
BR0107751A (pt) 2002-11-12

Similar Documents

Publication Publication Date Title
DZ3266A1 (fr) Pyrido[2,3-d]pyrimidine-2,7-diamine inhibiteurs de kinase
HRP20020798A2 (en) 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
NO20021694L (no) Pyrazolo[4,3-d]pyrimidinderivater
PT1235830E (pt) Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
DZ3218A1 (fr) Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase
DE60207241D1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidin-derivate
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
DE50001191D1 (de) Pyrazolo[4, 3-d]pyrimidine
NO20026247D0 (no) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidiner med en fosfodiesterase V-inhiberende virkning
MA26967A1 (fr) Derives de pyrimidine
DK1294729T3 (da) 2-aminoalkyl-thieno[2,3-d]pyrimidiner
PT1326866E (pt) 3,4-di-hidropirido[1,2-a]pirimidinas substituidas
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
DK1326866T3 (da) Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner